Prenetics Global Limited

Equities

PRE

KYG722451229

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-22 pm EDT			5-day change	1st Jan Change
5.77 ^USD	-1.70%		-3.35%	-2.37%

Apr. 01	Prenetics Global Limited Reports Impairment Loss of Goodwill for the Fourth Quarter Ended December 31, 2023	CI
Apr. 01	Prenetics Global Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Prenetics Global signs "transformational" $200mln deal to create cancer screening JV

June 30, 2023 at 08:01 am EDT

(via NewsDirect)

Prenetics Global Ltd (NASDAQ:PRE) CEO Danny Yeung speaks to Thomas Warner from Proactive after announcing a $200mln deal to create a multi-cancer early detection screening joint venture with Professor Dennis Lo. The new JV will be called Insighta and Yeung will serve as its first CEO. Yeung reveals plans to launch tests targeting lung and liver cancer in 2025, with a goal of selling over 30 million tests annually by 2030.

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

Latest news about Prenetics Global Limited

Prenetics Global Limited Reports Impairment Loss of Goodwill for the Fourth Quarter Ended December 31, 2023	Apr. 01	CI
Prenetics Global Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Prenetics Global Limited Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 01	CI
Earnings Flash (PRE) PRENETICS LIMITED Reports Q4 Revenue $5.4M	Apr. 01	MT
Prenetics Global Enters Preliminary Agreement With Metavisionaries on Space Research	Feb. 09	MT
Prenetics Global Limited Announces Board Appointments	Feb. 09	CI
Earnings Flash (PRE) PRENETICS LIMITED Reports Q3 Revenue $4.9M	Nov. 20	MT
Prenetics Global Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
Cantor Fitzgerald Adjusts Prenetics Global Price Target to $4 From $6, Maintains Overweight Rating	23-09-19	MT
Earnings Flash (PRE) PRENETICS LIMITED Reports Q2 Revenue $5.7M	23-09-15	MT
Prenetics Global Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-09-15	CI
Traders Assess Russia Turmoil, Driving Quiet Premarket Action for US Equity Futures	23-06-26	MT
Top Premarket Gainers	23-06-26	MT
Prenetics Global Forms JV With Hong Kong University Professor for Multi-Cancer Early Detection Screening	23-06-26	MT
Prenetics and Globally Renowned Scientist Prof. Dennis Lo Establishes USD 200 Million Joint Venture Insighta for Breakthrough Multi-Cancer Early Detection Screening	23-06-25	CI
Prenetics Global Limited Appoints Joel Neoh as Chief Consumer Officer	23-06-05	CI
Earnings Flash (PRE) PRENETICS LIMITED Reports Q1 Revenue $17.7M	23-06-05	MT
Prenetics Global Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-06-05	CI
Tranche Update on Prenetics Global Limited's Equity Buyback Plan announced on November 30, 2022.	23-05-01	CI
Tranche Update on Prenetics Global Limited's Equity Buyback Plan announced on November 30, 2022.	23-05-01	CI
Prenetics Global Limited Reports Impairment Charges for the Impairment Losses for the Three Months Ended December 31, 2022	23-03-14	CI
Prenetics Global Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
Earnings Flash (PRE) PRENETICS LIMITED Reports Q4 Revenue $52.3M	23-03-14	MT
Prenetics Global Limited Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-14	CI
Prenetics Global Limited Announces Formation of Scientific Advisory Board to Support New Business Strategy in Precision Oncology	23-03-02	CI

Chart Prenetics Global Limited

Duration

Period

More charts

Company Profile

Prenetics Global Ltd is a company mainly engaged in the diagnostics and genetic testing business. The Company operates its business through two segments. The Diagnostics segment is engaged in the provision of COVID-19 testing services and operation testing laboratories. The Segment is also engaged in the development of health monitoring systems. The Prevention segment is engaged in the provision of genetics testing services to individuals and corporate entities.

Sector

Biotechnology & Medical Research

Calendar

2024-06-02 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Prenetics Global Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.77 USD

Average target price

9 USD

Spread / Average Target

+55.98%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
PRENETICS GLOBAL LIMITED	-2.37%	71.72M
EXACT SCIENCES CORPORATION	-27.70%	9.88B
IOVANCE BIOTHERAPEUTICS, INC.	+27.06%	2.89B
GUARDANT HEALTH, INC.	-16.78%	2.88B
BGI GENOMICS CO., LTD.	-15.31%	2.12B
VERACYTE, INC.	-21.41%	1.67B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+68.70%	1.45B
CAREDX, INC	+29.75%	788M
SEEGENE, INC.	-5.02%	741M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-29.39%	514M

Bio Diagnostics & Testing